RecruitingPHASE1, PHASE2NCT05287945
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Oncorena AB
- Intervention
- Orellanine(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (3)
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
- Karolinska University Hospital, Stockholm, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05287945 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →